Arcus Biosciences, Inc.
RCUS · NYSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $1,341,589 | $1,413,400 | $1,488,960 | $2,806,412 |
| - Cash | $150,000 | $127,000 | $206,000 | $147,914 |
| + Debt | $60,000 | $11,000 | $120,000 | $116,887 |
| Enterprise Value | $1,251,589 | $1,297,400 | $1,402,960 | $2,775,385 |
| Revenue | $258,000 | $117,000 | $112,000 | $383,000 |
| % Growth | 120.5% | 4.5% | -70.8% | – |
| Gross Profit | $258,000 | $117,000 | $112,000 | $383,000 |
| % Margin | 100% | 100% | 100% | 100% |
| EBITDA | -$269,000 | -$291,000 | -$258,000 | $59,000 |
| % Margin | -104.3% | -248.7% | -230.4% | 15.4% |
| Net Income | -$283,000 | -$307,000 | -$267,000 | $53,000 |
| % Margin | -109.7% | -262.4% | -238.4% | 13.8% |
| EPS Diluted | -3.14 | -4.15 | -3.71 | 0.71 |
| % Growth | 24.3% | -11.9% | -622.5% | – |
| Operating Cash Flow | -$170,000 | -$306,000 | $438,000 | -$256,171 |
| Capital Expenditures | -$6,000 | -$24,000 | -$6,000 | -$26,078 |
| Free Cash Flow | -$176,000 | -$330,000 | $432,000 | -$282,249 |